Notably, the observed elevation of IgA in severe COVID-19 patients could be secondary to the natural abundance of IgA levels in both the respiratory and gastrointestinal systems; however, the possibility of cross-reactivity between IgA antibodies should be taken into consideration [31]. This evidence concerns the gene CD79A and COVID-19.